These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 17322284)

  • 1. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
    Jagadeeswaran R; Jagadeeswaran S; Bindokas VP; Salgia R
    Am J Physiol Lung Cell Mol Physiol; 2007 Jun; 292(6):L1488-94. PubMed ID: 17322284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
    Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
    Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
    Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
    Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
    Ma PC; Tretiakova MS; Nallasura V; Jagadeeswaran R; Husain AN; Salgia R
    Br J Cancer; 2007 Aug; 97(3):368-77. PubMed ID: 17667909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
    Maulik G; Madhiwala P; Brooks S; Ma PC; Kijima T; Tibaldi EV; Schaefer E; Parmar K; Salgia R
    J Cell Mol Med; 2002; 6(4):539-53. PubMed ID: 12611639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells.
    Usatyuk PV; Fu P; Mohan V; Epshtein Y; Jacobson JR; Gomez-Cambronero J; Wary KK; Bindokas V; Dudek SM; Salgia R; Garcia JG; Natarajan V
    J Biol Chem; 2014 May; 289(19):13476-91. PubMed ID: 24634221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Met is a potentially new therapeutic target for treatment of human melanoma.
    Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
    Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
    Kanteti R; El-Hashani E; Dhanasingh I; Tretiakova M; Husain AN; Sharma S; Sharma J; Vokes EE; Salgia R
    BMC Cancer; 2014 Mar; 14():185. PubMed ID: 24628993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines.
    Radtke S; Milanovic M; Rossé C; De Rycker M; Lachmann S; Hibbert A; Kermorgant S; Parker PJ
    J Cell Sci; 2013 Jun; 126(Pt 11):2381-91. PubMed ID: 23549785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
    Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
    Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.
    Voortman J; Harada T; Chang RP; Killian JK; Suuriniemi M; Smith WI; Meltzer PS; Lucchi M; Wang Y; Giaccone G
    Curr Pharm Des; 2013; 19(5):833-40. PubMed ID: 22973954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated O2(•−) and H2O2 mediated cell survival in SU11274-treated non-small-cell lung cancer A549 cells via c-Met-PI3K-Akt and c-Met-Grb2/SOS-Ras-p38 pathways.
    Liu Y; Shi QF; Ye YC; Tashiro S; Onodera S; Ikejima T
    J Pharmacol Sci; 2012; 119(2):150-9. PubMed ID: 22673163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
    Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R
    Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ephedrae herba stimulates hepatocyte growth factor-induced MET endocytosis and downregulation via early/late endocytic pathways in gefitinib-resistant human lung cancer cells.
    Nishimura Y; Hyuga S; Takiguchi S; Hyuga M; Itoh K; Hanawa T
    Int J Oncol; 2016 May; 48(5):1895-906. PubMed ID: 26983447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth.
    Cai W; Rook SL; Jiang ZY; Takahara N; Aiello LP
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1885-93. PubMed ID: 10845613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
    Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
    Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
    Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
    Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
    Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
    Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
    Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.